ArticleCancer cell2022
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.
Abstract readLetter
In one paragraph
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein.Viruses · 2026Article
- Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.Cancer medicine · 2025Article
- Article
- [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.BMC infectious diseases · 2024Article
- Article
- Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.Annals of hematology · 2024Article
- Safety and Immunogenicity of the ConvacellVaccines · 2024Article
- mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer.Journal for immunotherapy of cancer · 2024Article
- Use of remdesivir for COVID-19 in patients with hematologic cancer.Clinical and experimental medicine · 2023Article
- COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.The Journal of infectious diseases · 2023Review
- Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves.Cancer medicine · 2023Article
- Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.Current oncology (Toronto, Ont.) · 2023Article
- Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine ConvacellVaccines · 2023Article
- Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies.International journal of molecular sciences · 2023Review
- SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.Pathogens (Basel, Switzerland) · 2023Review
- [Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.Frontiers in immunology · 2023Article
- Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.Cancer research communications · 2022Article
- SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period.The Lancet. Rheumatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Maximilian J MairDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Manfred MittererHemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
Pia GattingerDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Julia M BergerDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Wolfgang TrutschnigDepartment of Artificial Intelligence and Human Interfaces and Intelligent Data Analytics Lab Salzburg, University of Salzburg, Salzburg, Austria.
Arne C BathkeDepartment of Artificial Intelligence and Human Interfaces and Intelligent Data Analytics Lab Salzburg, University of Salzburg, Salzburg, Austria.
Margaretha GanstererFaculty of Management and Economics, University of Klagenfurt, Klagenfurt, Austria.
Anna S BerghoffDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Severin LaengleDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Lynn GottmannDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Thomas BurattiHemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
Helmuth HaslacherDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Wolfgang W LammDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Markus RadererDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Selma TobudicDivision of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Thorsten FuerederDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Rudolf ValentaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Dominic FongHemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
Matthias PreusserDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: matthias.preusser@meduniwien.ac.at.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19NeoplasmsAntibodies, ViralHumansSARS-CoV-2Antibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.